shares of kronos bio inc kron jumped 25 in premarket trading on monday after the company announced a development deal with roche holding’s rog genentech kronos has a drug discovery platform that will be used to support genentech’s research in smallmolecule drugs for cancer as part of the agreement roche will pay 20 million upfront with milestone payments worth up to 554 million kronos’ stock has declined 864 over the past 12 months while the sp 500 spx is down 170